Literature DB >> 20680377

Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.

Daigoro Hirohama1, Junichi Hoshino, Eiko Hasegawa, Masayuki Yamanouchi, Noriko Hayami, Tatsuya Suwabe, Naoki Sawa, Fumi Takemoto, Yoshifumi Ubara, Shigeko Hara, Kenichi Ohashi, Kenmei Takaichi.   

Abstract

We report on a 33-year-old woman who presented with positive myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) during rheumatoid arthritis treatment with infliximab. She had a history of worsening arthralgia, and urinalysis showed the new occurrence of hematuria and proteinuria. Renal biopsy showed necrotizing crescentic glomerulonephritis. Immunosuppressive therapy and discontinuation of the infliximab therapy alleviated her arthralgia and improved the urinalysis results. We report this rare case in which an anti-tumor necrosis factor-α (TNF-α) agent for ANCA-associated systemic vasculitis was studied.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680377     DOI: 10.1007/s10165-010-0339-x

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  3 in total

Review 1.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

2.  Adalimumab-induced Anti-neutrophilic Cytoplasmic Antibody Vasculitis: A Rare Complication of an Increasingly Common Treatment.

Authors:  Tanya Chandra; Joy-Ann Tabanor-Gayle; Santhanam Lakshminarayanan
Journal:  Cureus       Date:  2019-09-09

Review 3.  Vasculitis induced by biological agents used in rheumatology practice: A systematic review.

Authors:  Camila da Silva Cendon Duran; Adriane Souza da Paz; Mittermayer Barreto Santiago
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.